Parkinson's Disease – Pipeline Assessment and Market Forecasts to 2016

March 25, 2011 - PRLog -- Report Reserve announces inclusion of a new market research report to its premium store.
GlobalData, the industry analysis specialist, has released its latest report, “Parkinson’s Disease - Pipeline Assessment and Market Forecasts to 2016  ” which provides the key data, information and analysis on the Parkinson’s disease (PD) market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecast seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with Parkinson’s disease, competitive assessment, the product profiles of the major marketed products and the promising drugs in the pipeline, an overview of the discontinued projects, the implications for future market competition, and the key players in the Parkinson’s disease market.

Epidemiological Factors are Estimated to Impel the Parkinson’s Disease Therapeutics Market Until 2016

Owing to several patent expirations in the forecast period, the market is estimated to sustain a low growth of 0.9% Compound Annual Growth Rate (CAGR) from 2009 to 2016. The epidemiological factors in the top seven markets will propel the Parkinson’s Disease (PD) therapeutics market to grow from $3,178m in 2009 to $3,384m by 2016. This low growth is ascribed to patent expirations, subsequent entry of generics and weak developmental pipeline. On the other hand, the ever increasing aged population in the USA, UK, Japan, Spain, Italy, Germany and France will increase the uptake of the generics.

Global Parkinson’s Disease Market Forecast 2001–2016

Source: GlobalData

Current Treatment Options Underserve the Market, Subsequently Allowing a Wide Scope for New Entrants.

GlobalData analyzed current treatment options in the PD market and deduced that Levodopa/Carbidopa combination is the corner stone of the treatment options. The current market is primarily driven by combinations, reformulations, and indication expansions. Of the branded products Boehringer Ingelheim’s Mirapex/Sifrol registered the highest sales in the 2008. This is followed by Glaxo’s Requip/Requip XL and Orion/Novartis‘ Stalevo. Boehringer Ingelheim, GlaxoSmithKline (GSK), Orion/Novartis, Teva/Lundbeck remain the leading competitors in the global PD market. The competitive landscape is populated by four major products, none of which is significantly stronger or more dominant than the others. Azilect that has shown promising results in the Phase III ADAGIO trials is indicated to inhibit the disease progression and is expected to positively impact the market.

As the drugs are only capable of treating the disease symptomatically, the market sustains high unmet need. The current treatment options, eventually becomes functionally ineffective and the patient stops responding to the drug. As a result the market presents wide scope for the new entrants. Any drug or therapy that potentially induces the brain to secrete dopamine will capture value in the market. The development of such a drug that can cause disease modification remains a challenge. The unmet need in the market is expected to rise in the forecast period.

Opportunity and Unmet Need in the Parkinson’s Disease Market, 2010

Source: GlobalData

Clinical Pipeline Hampered by Lack of Innovation

GlobalData finds that the global PD market is increasingly hampered by a lack of innovation. On the whole, the late stage pipeline consists of drugs that are aimed at the symptomatic treatment of the disease. Considering the huge burden of the disease and high expectations of patients, the pipeline is considered to be weak. Any company targeting to capture this unmet need, will need to overcome the prevailing product weaknesses such as adverse effects (dyskinesis, psychiatric side effects and obsessive compulsive behaviors) and limited efficacy. Currently, these are the biggest challenges preventing most pipeline products from capturing these unmet needs. There are 181 products in different developmental stages in 2010. The Phase III stage includes a mix of dopamine agonists and some drugs which are being developed to slow the disease progression. In addition, there are several promising stem cell and gene based therapies under development in early stages. However, these therapies are still in the early stages of clinical development and it is difficult to predict their success and time of commercialization.

Merck Serono, Acadia and Solvay with Significant Molecules in the Late Stage Development Will Lead the PD Pipeline in the near future

Of all the companies with PD pipeline molecules, Merck Serono, Acadia, Axxonis, Solvay, Avicena and Impax were envisaged to be the key future players. Merck Serono and Avicena have one molecule each in Phase III for PD. Axxonis has the patch and subcutaneous form of Lisuride in Phase III targeting patient compliance, Acadia has one molecule in Phase III and one in the preclinical stage,  Solvay has two drugs in Phase III development and Impax has one molecule in Phase III. Safinamide, Pimavanserin, PD-02 and SLV 308, currently in Phase III, are the key products in the pipeline. Safinamide, with features such as manifold mechanism of action and a high therapeutic index, remains the most keenly watched product in the pipeline. However, these pipeline products do not differ significantly from the marketed drugs in addressing the unmet need and in offering superior medical benefits. For more details, please vist http://www.reportreserve.com/reportdet.php?company=Global...

# # #

ReportReserve is an online research report distribution company. The company lists several market research reports published by several research houses across the globe.